secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001437749-26-014542
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene announces FDA agrees CNM-Au8 data may support accelerated approval NDA for ALS
--------------------------------------------------------------------------------

- FDA stated proposed data may support NDA submission under accelerated approval pathway for ALS.
- FDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.
- Clene expects to submit NDA for CNM-Au8 in Q3 2026; Phase 3 confirmatory study to start Q1 2027.
- NDA supported by NfL and clinical data from Phase 2 trials and NIH-sponsored Expanded Access Protocol.
- CNM-Au8 previously received Orphan Drug Designation from FDA for ALS treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926014542/0001437749-26-014542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926014542/clnn20260503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-014542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer